Phreesia (NYSE:PHR) Announces Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Key Points

• Phreesia beat quarterly earnings expectations, reporting adjusted EPS of $0.05 versus the $0.02 consensus estimate, while revenue came in at $130.94 million, slightly above forecasts.
• The stock rose 2.2% after the report, trading around $9.15, though it remains well below its 52-week high of $32.76 and has a consensus analyst rating of Hold.
• Investor sentiment is being pressured by ongoing shareholder litigation, with multiple firms advertising a class-action lawsuit over alleged misleading statements about Phreesia’s growth prospects and deadline reminders for lead-plaintiff claims.

Phreesia (NYSE:PHR - Get Free Report) issued its earnings results on Wednesday. The company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.03, FiscalAI reports. Phreesia had a net margin of 0.48% and a return on equity of 3.23%. The business had revenue of $130.94 million for the quarter, compared to analyst estimates of $130.08 million.

Phreesia Stock Up 2.2%

Shares of PHR traded up $0.20 during trading hours on Wednesday, reaching $9.15. 1,383,433 shares of the stock traded hands, compared to its average volume of 1,798,752. The company has a current ratio of 1.53, a quick ratio of 1.53 and a debt-to-equity ratio of 0.41. The stock has a fifty day simple moving average of $9.57 and a 200 day simple moving average of $13.78. Phreesia has a 52 week low of $7.77 and a 52 week high of $32.76. The company has a market cap of $565.05 million, a price-to-earnings ratio of 304.90 and a beta of 0.89.

Analysts Set New Price Targets

A number of research analysts have weighed in on PHR shares. BMO Capital Markets dropped their price objective on shares of Phreesia from $32.00 to $14.00 and set an "outperform" rating on the stock in a research note on Tuesday, March 31st. Stephens dropped their target price on Phreesia from $32.00 to $20.00 and set an "overweight" rating on the stock in a report on Tuesday, March 31st. Weiss Ratings restated a "sell (e+)" rating on shares of Phreesia in a report on Wednesday, January 28th. Citigroup restated a "neutral" rating and issued a $10.00 target price (down from $25.00) on shares of Phreesia in a report on Tuesday, March 31st. Finally, Citizens Jmp restated a "market perform" rating on shares of Phreesia in a report on Wednesday, April 1st. Ten equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Phreesia currently has a consensus rating of "Hold" and a consensus price target of $19.06.

Key Phreesia News

Here are the key news stories impacting Phreesia this week:

• Negative Sentiment: A shareholder class action lawsuit has been filed alleging Phreesia made false and misleading statements or omitted material facts about its growth prospects, especially around slowing growth in Network Solutions. Article Title
• Negative Sentiment: Multiple law firms issued reminders and recruitment notices for the July 13, 2026 lead-plaintiff deadline, keeping the lawsuit in focus and increasing overhang on the shares. Article Title
• Negative Sentiment: Levi & Korsinsky said Phreesia’s March 30 corrective disclosure allegedly revealed concealed weakness in pharmaceutical marketing, which it claims wiped out about $3.03 per share in value. Article Title
• Neutral Sentiment: Several firms, including Rosen, Pomerantz, Howard G. Smith, Frank R. Cruz, Faruqi & Faruqi, and others, reiterated that a class action is already underway and that investors may seek to be lead plaintiffs by the deadline. Article Title

Insider Activity

In related news, insider Yvonne Hui sold 10,063 shares of the firm's stock in a transaction dated Thursday, April 16th. The shares were sold at an average price of $9.08, for a total transaction of $91,372.04. Following the transaction, the insider directly owned 25,991 shares of the company's stock, valued at $235,998.28. This trade represents a 27.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Balaji Gandhi sold 3,829 shares of the firm's stock in a transaction dated Wednesday, March 25th. The stock was sold at an average price of $11.26, for a total transaction of $43,114.54. Following the sale, the chief financial officer owned 146,740 shares of the company's stock, valued at $1,652,292.40. This trade represents a 2.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 50,493 shares of company stock valued at $461,983 over the last ninety days. Company insiders own 5.20% of the company's stock.

Institutional Trading of Phreesia

A number of large investors have recently bought and sold shares of PHR. Prosight Management LP purchased a new position in shares of Phreesia in the fourth quarter worth about $16,533,000. Millennium Management LLC grew its stake in Phreesia by 730.7% during the third quarter. Millennium Management LLC now owns 1,064,132 shares of the company's stock valued at $25,028,000 after acquiring an additional 936,033 shares in the last quarter. Jacobs Levy Equity Management Inc. purchased a new position in Phreesia during the fourth quarter valued at approximately $15,213,000. JPMorgan Chase & Co. grew its stake in Phreesia by 807.7% during the fourth quarter. JPMorgan Chase & Co. now owns 507,220 shares of the company's stock valued at $8,582,000 after acquiring an additional 451,339 shares in the last quarter. Finally, Franklin Resources Inc. grew its stake in Phreesia by 28.8% during the fourth quarter. Franklin Resources Inc. now owns 2,000,082 shares of the company's stock valued at $33,841,000 after acquiring an additional 446,890 shares in the last quarter. 92.10% of the stock is owned by hedge funds and other institutional investors.

About Phreesia

Phreesia, Inc NYSE: PHR is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company's cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.